Literature DB >> 16237480

Safety issues concerning the medical use of cannabis and cannabinoids.

Mark A Ware1, Vivianne L Tawfik.   

Abstract

Safety issues are a major barrier to the use of cannabis and cannabinoid medications for clinical purposes. Information on the safety of herbal cannabis may be derived from studies of recreational cannabis use, but cannabis exposure and effects may differ widely between medical and recreational cannabis users. Standardized, quality-controlled cannabinoid products are available in Canada, and safety profiles of approved medications are available through the Canadian formulary. In the present article, the evidence behind major safety issues related to cannabis use is summarized, with the aim of promoting informed dialogue between physicians and patients in whom cannabinoid therapy is being considered. Caution is advised in interpreting these data, because clinical experience with cannabinoid use is in the early stages. There is a need for long-term safety monitoring of patients using cannabinoids for a wide variety of conditions, to further guide therapeutic decisions and public policy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237480     DOI: 10.1155/2005/312357

Source DB:  PubMed          Journal:  Pain Res Manag        ISSN: 1203-6765            Impact factor:   3.037


  9 in total

Review 1.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

2.  Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.

Authors:  Gai Ling Li; Helen Winter; Rosalin Arends; Gary W Jay; Vu Le; Tim Young; John P Huggins
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

Review 3.  Adverse effects of medical cannabinoids: a systematic review.

Authors:  Tongtong Wang; Jean-Paul Collet; Stan Shapiro; Mark A Ware
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

4.  Macro and Trace Elements in Hemp (Cannabis sativa L.) Cultivated in Greece: Risk Assessment of Toxic Elements.

Authors:  Effrosyni Zafeiraki; Konstantinos M Kasiotis; Paul Nisianakis; Kyriaki Machera
Journal:  Front Chem       Date:  2021-04-22       Impact factor: 5.221

5.  Early phenylpropanoid biosynthetic steps in Cannabis sativa: link between genes and metabolites.

Authors:  Teresa Docimo; Roberto Consonni; Immacolata Coraggio; Monica Mattana
Journal:  Int J Mol Sci       Date:  2013-06-28       Impact factor: 5.923

6.  Medical cannabis use in Canada: vapourization and modes of delivery.

Authors:  Samantha Shiplo; Mark Asbridge; Scott T Leatherdale; David Hammond
Journal:  Harm Reduct J       Date:  2016-10-29

7.  A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects.

Authors:  Klaus Schaffler; Ashraf Yassen; Peter Reeh; Paul Passier
Journal:  Pain Med       Date:  2018-06-01       Impact factor: 3.750

8.  Identification of candidate genes affecting Delta9-tetrahydrocannabinol biosynthesis in Cannabis sativa.

Authors:  M David Marks; Li Tian; Jonathan P Wenger; Stephanie N Omburo; Wilfredo Soto-Fuentes; Ji He; David R Gang; George D Weiblen; Richard A Dixon
Journal:  J Exp Bot       Date:  2009-07-06       Impact factor: 6.992

9.  Galenic Preparations of Therapeutic Cannabis sativa Differ in Cannabinoids Concentration: A Quantitative Analysis of Variability and Possible Clinical Implications.

Authors:  Alessandra Bettiol; Niccolò Lombardi; Giada Crescioli; Valentina Maggini; Eugenia Gallo; Alessandro Mugelli; Fabio Firenzuoli; Roberto Baronti; Alfredo Vannacci
Journal:  Front Pharmacol       Date:  2019-01-17       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.